Connect your AI

Wave Life Sciences WVE Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

Sarepta Therapeutics, Inc.SRPT

$29.4M-29.0%

Ionis PharmaceuticalsIONS

$43.28M+45.6%

Madrigal Pharmaceuticals, Inc.MDGL

$34.02M+62.5%

ALN

Alnylam PharmaceuticalsALNY

$70.15M+23.7%

Beam TherapeuticsBEAM

$19.04M-28.6%

Other financials

Income statement

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Cash flow

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Profitability

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Wave Life Sciences's stock-based comp?: Wave Life Sciences (WVE) reported stock-based comp of $9.06M in Q1 2026.
How has Wave Life Sciences's stock-based comp changed year-over-year?: Wave Life Sciences's stock-based comp increased by 83.0% year-over-year, from $4.95M to $9.06M.
What is the long-term trend for Wave Life Sciences's stock-based comp?: Over 4 years (2021 to 2025), Wave Life Sciences's stock-based comp has grown at a 11.1% compound annual growth rate (CAGR), from $16.41M to $24.97M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.